Indaptus Therapeutics, Inc.INDP

Market cap

$11.85M

P/E ratio

	Dec 31, 2021	Dec 31, 2022
Net loss	-7,711,386	-14,322,798
Depreciation	1,403	1,781
Stock-based compensation	2	3
Realized gain on assets held for sale	-	24,155
Realized gain on marketable securities	-	110,002
Prepaid expenses and other current assets	837,917	-295,220
Accounts payable and other current liabilities	-4,236,656	-1,154,829
Other assets	16,477	721,774
Operating lease right-of-use asset and liability, net	240	961
Net cash used in operating activities	-11,290,535	-13,078,347
Proceeds received for assets held for sale	451,600	172,555
Purchases of property and equipment	3,854	-
Purchase of marketable securities	-	30
Maturity of marketable securities	-	13
Net cash (used in) provided by investing activities	447,746	-16,427,018
Proceeds from merger	16	-
Decoy's transaction costs	665,627	-
Issuance of pre-funded warrants and warrants	30	-
Issuance costs of Private Placement	3	-
Exercise of pre-funded warrants	27,273	-
Proceeds from SAFEs, net	5	-
Exercise of stock options	363,058	-
Net cash provided by financing activities	48	-
Net (decrease) increase in cash and cash equivalents	37	-29,505,365
Conversion of preferred stock	8,359	-
Conversion of SAFEs	6	-
Initial recognition of operating right-of-use asset and lease liability upon lease commencement	183,480	-
Reclass from non-current assets to current assets	44,445	-
Release of deposit upon closing of merger	200,000	-
Issuance of initial commitment shares	-	1,425
Change in unrealized gain on marketable securities	-	96,434
Cash paid for income taxes	-	2,400
Cash received for interest earned on deposits	5,141	111,018